Effect of socioeconomic status as measured by education level on survival in breast cancer clinical trials

Psycho-Oncology

Volumn 22, Issue 2, 2013, Pages 315-323

  Herndon, James E ^a   Kornblith, Alice B ^b   Holland, Jimmie C ^c   Paskett, Electra D ^d  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

breast cancer; education; oncology; SES; survival

Indexed keywords

CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; MEGESTROL ACETATE; PACLITAXEL; PROGESTERONE RECEPTOR; TAMOXIFEN; TOPOTECAN; TRASTUZUMAB;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; BONE MARROW TRANSPLANTATION; BONE METASTASIS; BREAST CANCER; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; DRUG MEGADOSE; EDUCATIONAL STATUS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; RISK FACTOR; SOCIAL STATUS; TUMOR VOLUME; VISCERAL METASTASIS;

ADULT; AFRICAN AMERICANS; AGED; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; EDUCATIONAL STATUS; FEMALE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SOCIAL CLASS; SURVIVAL RATE; UNITED STATES;

EID: 84873406545     PISSN: 10579249     EISSN: 10991611     Source Type: Journal    
DOI: 10.1002/pon.2094     Document Type: Article

References (62)

1. House JS, Landis KR, Umberson D,. Social relationships and health. Science 1988; 241: 540-545.
2. Marmot M,. Social determinants of health equalities. Lancet 2005; 365: 1099-1104.
3. Lynch JW, Smith GD, Kaplan GA, et al,. Income inequality and mortality: importance to health of individual income, psychosocial environment, or material conditions. BMJ 2000; 320: 1200-1204.
4. Marmot M, Ryff CD, Bumpass LL, et al., Social inequalities in health: next questions and converging evidence. Soc Sci Med 1997; 44 (6): 901-910.
5. Marmot M, Wilkinson RG,. Psychosocial and material pathways in the relations between income and health: a response to Lynch et al. BMJ 2001; 322: 1233-1236.
6. Marmot M,. The influence of income on health: views of an epidemiologist. Health Aff 2002; 21 (2): 31-46.
7. Yabroff KR, Gordis L,. Does stage at diagnosis influence the observed relationship between socioeconomic status and breast cancer incidence, case-fatality, and mortality? Soc Sci Med 2003; 57: 2265-2279.
8. Cross CK, Harris J, Recht A,. Race, socioeconomic status, and breast carcinoma in the U.S.: what have we learned from clinical studies? Cancer 2001; 95: 1988-99.
9. Gorey KM, Kliewer E, Holowaty EJ, et al., An international comparison of breast cancer survival: Winnipeg, Manitoba and Des Moines, Iowa metropolitan areas. Ann Epidemiol 2002; 13: 32-41.
10. Mariotto A, Capocaccia R, Verdecchia A, et al., Projecting SEER cancer survival rates to the US: an ecological regression approach. Cancer Causes Control 2002; 13: 101-111.
11. Coleman MP, Babb P, Sloggett A, et al., Socioeconomic inequalities in cancer survival in England and Wales. Cancer 2001; 91: 208-16.
12. Vigano A, Bruera E, Jhangri GS, et al., Clinical survival predictors in patients with advanced cancer. Arch Intern Med 2000; 160: 861-868.
13. Mackillop WJ, Zhang-Salomons J, Groome PA, et al., Socioeconomic status and cancer survival in Ontario. JCO 1997; 15: 1680-1689.
14. Goodwin JS, Samet JM, Hunt WC,. Determinants of survival in older cancer patients. JNCI 1996; 88 (15): 1031-81.
15. Stavraky KM, Skillings JR, Stitt LW, et al., The effect of socioeconomic status on the long-term outcome of cancer. J Clin Epid 1996; 49 (10): 1155-1160.
16. Dale W, Vijayakumar S, Lawlor EF, et al., Prostate cancer, race, and socioeconomic status: inadequate adjustment for social factors in assessing racial differences. Prostate 1996; 29 (5): 271-281.
17. Greenwald HP, Borgatta EF, McCorkle R, et al., Explaining reduced cancer survival among the disadvantaged. Milbank Q 1996; 72 (2): 215-238.
18. Bouchardy C, Fioretta G, DePerrot M, et al,. Determinants of long term survival. Cancer 1999; 86: 2229-2237.
19. Robbins AS, Yin D, Parikh-Patel A,. Differences in prognostic factors and survival among White men and Black men with prostate cancer, California, 1995-2004. Am J Epidemiol 2007; 166: 71-78.
20. Reyes-Ortiz CA, Goodwin JS, Freeman JL,. The effect of socioeconomic factors on incidence, stage at diagnosis and survival of cutaneous melanoma. Med Sci Monit 2005; 11 (5): RA163-172.
21. Lehto US, Ojanen M, Dyba T, et al., Baseline psychosocial predictors of survival in localized breast cancer. BJC 2006; 94: 1245-1252.
22. Dejardin O, Remontet L, Bouvier AM, et al., Socioeconomic and geographic determinants of survival of patients with digestive cancer in France. BJC 2006; 95: 944-949.
23. Abou-Jawde RM, Baz R, Walker E, et al., The role of race, socioeconomic status, and distance traveled on the outcome of African-American patients with multiple myeloma. Haematologica 2006; 91 (10): 1410-1431.
24. Coker AL, Du XL, Fang S,. Socioeconomic status and cervical cancer survival among older women: findings from the SEER-Medicare linked data cohorts. Gynecol Oncol 2006; 102: 278-284.
25. Kaffashian F, Godward S, Davies T, et al., Socioeconomic effects on breast cancer survival: proportion attributable to stage and morphology. BJC 2003; 89: 1693-1696.
26. Bouchardy C, Verkooijen HM, Fioretta G,. Social class is an important and independent prognostic factor of breast cancer mortality. Int J Cancer 2006; 119: 114-1151.
27. Dalton SO, Ross L, During M, et al., Influence of socioeconomic factors on survival after breast cancer-a nationwide cohort study of women diagnosed with breast cancer in Denmark 1983-1999. Int J Cancer 2007; 121: 2524-2531.
28. Thomson CS, Hole DJ, Twelves CJ, et al., Prognostic factors in women with breast cancer: distribution by socioeconomic status and effect on differences in survival. J Epidemiol Community Health 2001; 55: 308-315.
29. Menvielle G, Leclerc A, Chastang JF, et al., Social inequalities in breast cancer mortality among French women: disappearing educational disparities from 1968 to 1996. BJC 2006; 94: 152-155.
30. Albano JD, Ward E, Jemal A, et al., Cancer mortality in the United States by education and race. JNCI 2007; 99: 1384-94.
31. Gordon NH,. Socioeconomic factors and breast cancer in black and white Americans. Cancer and Metastasis 2003; 22: 55-64.
32. Gordon NH, Crowe JP, Brumberg DJ, et al., Socioeconomic-factors and race in breast cancer recurrence and survival. Am J Epidemiol 1992; 6: 609-618.
33. Cella DF, Orav EJ, Kornblith AB, et al., Socioeconomic status and cancer survival. JCO 1991; 9: 1500-1509.
34. Herndon JE II, Kornblith AB, Holland JC, et al., Patient education level as a predictor of survival in lung cancer clinical trials. JCO 2008; 26: 4116-4123.
35. Holland JC, Herndon J, Kornblith AB, et al,. A sociodemographic data collection model for cooperative clinical trials. PASCO 1992; 11: 157. Abstract 445.
36. Abrams J, Aisner J, Cirrincione C, et al,. Dose-response trial of megestrol acetate in advanced breast cancer: Cancer and Leukemia Group B Phase III study 8741. JCO 1999; 17: 64-73.
37. Kornblith AB, Hollis DR, Zuckerman E, et al., Effect of megestrol acetate upon quality of life in a dose response trial with advanced breast cancer patients. JCO 1993; 11: 2081-2089.
38. Peters WP, Rosner GL, Vredenburgh JJ, et al., Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13. JCO 2005; 23: 2191-2200.
39. Peppercorn J, Herndon J II, Kornblith AB, et al., Quality of life among patients with stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066. Cancer 2005; 104: 1580-9.
40. Parnes HL, Cirrincione C, Aisner J, et al., Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140. JCO 2003; 21: 1819-1824.
41. Liu MC, Demetri GD, Berry DA, et al., Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel. Cancer Treatment Review 2008; 34: 223-230.
42. Levine EG, Cirrincione CT, Szatrowski TP, et al., Phase II trial of topotecan in advanced breast cancer: a Cancer and Leukemia Group B study. American JCO 1999; 22 (3): 218-222.
43. Winer EP, Berry DA, Woolf S, et al,. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and Leukemia Group B trial 9342. JCO 2004; 22 (11): 2061-2068.
44. Hughes KS, Schnaper LA, Berry D, et al., Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. NEJM 2004; 351: 971-7.
45. Henderson IC, Berry DA, Demetri GD, et al., Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. JCO 2003; 21: 976-983.
46. Citron ML, Berry DA, Cirrincione C, et al., Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as post-operative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial C9741/Cancer and Leukemia Group B trial 9741. JCO 2003; 21: 1431-1439.
47. Seidman AD, Berry D, Cirrincione C, et al., Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. JCO 2008; 26: 1642-1649.
48. Kaplan EL, Meier P,. Nonparametric estimation from incomplete observations. JASA 1958; 53: 457-481.
49. Brookmeyer R, Crowley J,. A confidence interval for the median survival time. Biometrics 1982; 38: 29-41.
50. Hosmer DW, Lemeshow S,. Applied Survival Analysis. John Wiley & Sons, 1999.
51. Cox DR,. Regression models and life tables (with discussion). JRSS-B 1972; 34: 187-220.
52. Meara ER, Richards S, Cutler DM,. The gap gets bigger: changes in mortality and life expectancy, by education, 1981-2000. Health Aff 2008; 27: 350-360.
53. Hahn KME, Bondy ML, Selvan M, et al., Factors associated with advanced disease stage at diagnosis in a population-based study of patients with newly diagnosed breast cancer. AJE 2007; 166: 1035-1044.
54. McCarthy EP, Burns RB, Coughlin SS, et al., Mammography use helps to explain differences in breast cancer stage at diagnosis between older black and white women. Ann Intern Med 1998; 128: 729-736.
55. Li DI, Malone KE, Daling JR,. Differences in breast cancer stage, treatment, and survival by race and ethnicity. Arch Intern Med 2003; 163: 49-56.
56. Gorin SS, Heck JE, Cheng B, et al., Delays in breast cancer diagnosis and treatment by racial/ethnic group. Arch Intern Med 2006; 166: 224-2252.
57. Dailey AB, Kasl SV, Holford TR, et al., Neighborhood-level socioeconomic predictors of nonadherence to mammography screening guidelines. Cancer Epidemiol Biomarkers Prev 2007; 16: 2293-2303.
58. Newman LA, Griffith KA, Jatoi I, et al., Meta-analysis of survival in African American and white American patients with breast cancer: ethnicity compared with socioeconomic status. JCO 2006; 24: 1342-1349.
59. Albain KS, Unger JM, Crowley JJ, et al., Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. JNCI 2009; 101: 984-992.
60. Polite BN, Cirrincione C, Fleming GF, et al., Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840-Cancer and Leukemia Group B. JCO 2008; 26 (16): 2659-2664.
61. Blackstock AW, Herndon JE II, Paskett ED, et al., Outcomes among African-American/non-African-American patients with advanced non-small-cell carcinoma: report from the Cancer and Leukemia Group B, JNCI 2002; 94: 284-90.
62. Blackstock AW, Herndon JE II, Paskett ED, et al., Similar outcomes between African American and non-African American patients with extensive-stage small-cell lung carcinoma: report from the Cancer and Leukemia Group B. JCO 2006; 24 (3): 407-412.